Skip to content

Personalized Medicine

News

Top Stories

Despite Utility, NGS Testing for Cancer Often Denied Insurance Coverage(link is external and opens in a new window)

Source:

Journal of Clinical Pathways

Expanded genomic panel testing was clinically impactful in most patients with high-risk cancer, yet payers reimbursed only 10.75% of the charge on average, if reimbursed at all, new study found.

Topic

Cancer